NCT07205731
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07205731
Title Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma (SAFE ESO)
Acronym SAFE ESO
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Hospital, Clermont-Ferrand
Indications
Therapies
Age Groups: senior
Covered Countries FRA


No variant requirements are available.